Masayuki Tanahashi

Dr. Masayuki Tanahashi

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Clinical Lung Cancer
Verified
Journal Article
Closed access
AHAkira Hamada
Akira Hamada
JSJunichi Soh
Junichi Soh
AHAkito Hata
Akito Hata
KNKiyoshi Nakamatsu
Kiyoshi Nakamatsu
MSMototsugu Shimokawa
Mototsugu Shimokawa
TMTetsuya Mitsudomi
Tetsuya Mitsudomi

1 September 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
MTMasayuki Tanahashi
Masayuki Tanahashi
HNHiroshi Niwa
Hiroshi Niwa
HYHaruhiro Yukiue
Haruhiro Yukiue
ESEriko Suzuki
Eriko Suzuki
HHHiroshi Haneda
Hiroshi Haneda
NYNaoko Yoshii
Naoko Yoshii

16 March 2019 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
YKYasunori Kaminuma
Yasunori Kaminuma
MTMasayuki Tanahashi
Masayuki Tanahashi
HYHaruhiro Yukiue
Haruhiro Yukiue
ESEriko Suzuki
Eriko Suzuki
NYNaoko Yoshii
Naoko Yoshii
HNHiroshi Niwa
Hiroshi Niwa
Micronodular thymoma with lymphoid stroma is a rare subtype of thymoma. Here we report a case of micronodular thymoma with lymphoid stroma that was completely resected after incomplete resection 10 years earlier. A 70-year-old Japanese woman who had undergone resection for a thymic cyst 10 years earlier was found to have a solid nodule with a multilocular lesion at the site of the previous operation. We suspected that the tumor was a malignant tumor and performed trans-sternal radical thymectomy and diagnosed the lesion as micronodular thymoma with lymphoid stroma pathologically. When we reassessed the thymic cyst that had been resected 10 years earlier, a few lesions of micronodular thymoma with lymphoid stroma were found in the cyst wall. Based on these findings, we concluded that only the cystic component of micronodular thymoma with lymphoid stroma had been removed, and that the residual lesion grew locally over the next 10 years before being completely resected by reoperation. We experienced an unusual case of micronodular thymoma with lymphoid stroma, which is a rare subtype of thymoma. Greater care should be taken to exclude a thymoma with a cystic lesion, even if a thymic cyst is strongly suspected on computed tomography and magnetic resonance imaging.

26 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Takuya WatanabeTakuya Watanabe
Takuya Watanabe
MTMasayuki Tanahashi
Masayuki Tanahashi
ESEriko Suzuki
Eriko Suzuki
NYNaoko Yoshii
Naoko Yoshii
TKTakuya Kohama
Takuya Kohama
TETakumi Endo
Takumi Endo
Twenty years have passed since uniportal video-assisted thoracoscopic surgery (VATS) was first reported. Several reports have already proven the minimal invasiveness of uniportal VATS. In addition, two large clinical trials recently demonstrated the benefits of segmentectomy for small peripheral early-stage non-small cell lung cancer. Uniportal VATS segmentectomy is considered the most beneficial minimally invasive surgery for patients with early-stage lung cancer. However, a high level of skill and experience are required to achieve this goal. Only a few reports have discussed specific techniques, particularly for complex segmentectomies. In this Special Issue, we reviewed previous reports on uniportal VATS segmentectomy regarding the indications, instrument selection, marking of the tumor location, methods of intersegmental plane identification, and lymph node dissection, including our own techniques with video content.

11 May 2022 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
MTMasayuki Tanahashi
Masayuki Tanahashi
ESEriko Suzuki
Eriko Suzuki
NYNaoko Yoshii
Naoko Yoshii
TWTakuya Watanabe
Takuya Watanabe
HTHiroyuki Tsuchida
Hiroyuki Tsuchida
MNMinori Nakamura
Minori Nakamura
OBJECTIVES: The present study compared the utility of fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) for predicting the pathological response and prognosis following neoadjuvant therapy for locally advanced non-small-cell lung cancer (NSCLC). METHODS: This retrospective analysis included 72 patients in whom adjacent structures showed involvement and/or cN2 NSCLC who received induction chemoradiotherapy (ICRT) and subsequent surgery at our hospital from 2008 to 2019. FDG-PET and CT were performed in all patients before and after ICRT using the same scanner with similar techniques. We calculated the reduction in the maximum standardized uptake value in FDG-PET (ΔSUVmax) and tumour size on CT (ΔCT-size) before and after ICRT and investigated the relationship between the pathological response and prognosis. RESULTS: The disease response was classified as a major pathological response in 43 patients, and a minor response in 29 patients. ΔSUVmax 60% and ΔCT-size 30% were identified as the optimal cut-off values for predicting a major pathological response. ΔSUVmax was superior to ΔCT-size in terms of sensitivity, specificity, positive predictive value and negative predictive value. Furthermore, ΔSUVmax was superior to ΔCT-size for predicting the prognosis. CONCLUSIONS: Based on the results of the present study, FDG-PET appeared to have greater utility than CT in predicting the pathological response following ICRT and the postoperative prognosis in patients with locally advanced NSCLC.

9 April 2020 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
YKYasunori Kaminuma
Yasunori Kaminuma
MTMasayuki Tanahashi
Masayuki Tanahashi
ESEriko Suzuki
Eriko Suzuki
NYNaoko Yoshii
Naoko Yoshii
HNHiroshi Niwa
Hiroshi Niwa
Objectives: Lung cancer patients have been reported to have a high incidence of venous thromboembolism (VTE) and a high recurrence rate of VTE. However, there are no detailed reports of VTE in lung cancer patients who underwent surgery after induction therapy. We examined the incidence and clinical features of VTE in these patients. Methods: We retrospectively evaluated 89 patients with non-small cell lung cancer who underwent surgery after induction therapy at our department between April 2009 and March 2018. The incidence of VTE, clinical features, and long-term prognosis were retrospectively examined. Results: Among the 89 patients, 4 (4.5%) developed VTE, and there was no significant difference in the background characteristics between patients with and without VTE. All four patients developed VTE during preoperative treatment. In the patients with VTE, anticoagulant therapy with oral anticoagulants was administered after heparinization, and the median duration of anticoagulant therapy was 18.7 months. There were no cases of symptomatic VTE recurrence after surgery, regardless of lung cancer recurrence. Although the overall survival (OS) showed no significant difference between patients with and without VTE, the disease-free survival was significantly shorter in patients with VTE than in those without it (median 6.3 vs. 71.6 months, p < 0.01). Conclusions: In induction cases, the incidence of VTE was 4.5%, and it can at least be stated that no symptomatic VTE developed or recurred after surgery. Patients with VTE in induction therapy had short progression-free survival and required careful follow-up after surgery.